Physician profile
William Castle
NPI 1538138391
$4,086.64
in general payments reported to CMS, 2019-2025
34 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $404 · 2021: $201 · 2022: $429 · 2023: $696 · 2024: $763 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,836.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $611.19 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $493.40 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $361.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $319.14 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $278.04 | 2019-2025 | Veozah |
| Amgen INC. | $270.26 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $226.38 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $204.25 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $177.21 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $150.75 | 2022-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.68 | 2019-2023 | |
| Exact Sciences Corporation | $107.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $93.35 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $86.66 | 2021-2022 | |
| Axsome Therapeutics, INC. | $72.88 | 2025 | Auvelity |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.69 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.33 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $44.03 | 2020 | |
| Allergan, INC. | $38.76 | 2019-2020 | |
| Shield Therapeutics INC | $34.82 | 2023-2024 | Accrufer |
| Genentech USA, INC. | $32.92 | 2019 | |
| Amarin Pharma, INC. | $31.12 | 2020-2021 | |
| Gilead Sciences, INC. | $30.28 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $25.87 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $20.00 | 2025 | Gardasil 9, Capvaxive |
| Daiichi Sankyo INC. | $19.66 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $18.08 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.02 | 2022 | |
| Medtronic, INC. | $15.73 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.69 | 2022 | |
| Currax Pharmaceuticals LLC | $15.29 | 2024 | Onzetra Xsail, Contrave |
| Lexicon Pharmaceuticals, INC. | $14.18 | 2020 | |
| Hikma Pharmaceuticals USA | $12.83 | 2019 | |
| Adlon Therapeutics L.P. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Castle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.